Stocks / BDX vs IDXX
BDX vs IDXX
Becton, Dickinson and Company and IDEXX Laboratories, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Becton, Dickinson and Company (BDX) | IDEXX Laboratories, Inc. (IDXX) | |
|---|---|---|
| Market cap | $41.9B | $45.7B |
| Revenue (latest FY) | $21.84B | $4.30B |
| Net income (latest FY) | $1.68B | $1.06B |
| Revenue growth (5y CAGR) | 6.3% | 9.7% |
| Net margin | 7.7% | 24.6% |
| Return on equity | 6.6% | 66.0% |
| P/E ratio | 26.5 | 42.6 |
| Dividend yield | 2.8% | — |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BDX — free Open IDXX — freeFrequently asked questions
Which is bigger, BDX or IDXX?
IDEXX Laboratories, Inc. is larger by market capitalization — $45.7B versus $41.9B.
Which grows faster, BDX or IDXX?
Over the last five fiscal years, IDEXX Laboratories, Inc. grew revenue faster — 9.7%/yr versus 6.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.